Deep dive: The oral obesity wars

Leave a Comment / By /

BioSpace examines how the FDA approval of Eli Lilly’s oral obesity drug Foundayo has ignited a key race with Novo Nordisk.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top